Author Archives: admin


Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,…

In the forecast period, the global stem cell therapy market is expected to generate revenue about 978 million USD in 2027, growing at a CAGR of 20% by 2019-2027.

Stem cells are found in all human beings, from the initial stages of human growth to the end of life. All stem cells are beneficial for medical research; however, each of the different kinds of stem cells has both limitations and promise. Embryonic stem cells that can be obtained from a very initial stage in human development have the prospect to develop all of the cell types in the human body. Adult stem cells are found in definite tissues in fully developed humans. Stem Cell Therapy Market are basic cells of all multicellular animals having the ability to differentiate into a wide range of adult cells. Totipotency and self-renewal are characteristics of stem cells. However, totipotency is seen in very early embryonic stem cells.

Report Consultant has added a new report to its database that qualifies an expressive and professional look into this market. The report is titled a Global stem cell therapy Market. Thus, the report scrutinizes the present-day environment of the market in order to generate a comprehensive understanding of the future plans of the market. Porters five and SWOT analysis have been utilized to scrutinize the Global stem cell therapy Market.

Grab Eye-Popping Black Friday Deals on this Report @

Top Key Players:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, and Takeda (TiGenix)

The report provides a brief timeline for each segment of the stem cell therapy market. Key drivers and restraints impacting the market segments are also demonstrated precisely. It also helps in determining reasons for the progress of certain segments over others in the looming years. The overall market is also segmented on the basis of geography in the United States, Europe, India, Japan, China, and Southeast Asia. The geographical segmentation provides a distinct assessment of the factors supporting these regions, the favorable regulatory policies, and the impact of the political frameworks.

The global stem cell therapy market report is integrated considering the primary and secondary research methodologies that have been collected from reliable sources intended to generate a factual database. The data from market journals, publications, conferences, white papers and interviews of key market leaders are compiled to generate our segmentation and is mapped to a fair trajectory of the market during the forecast period.

Get Sample Copy of Report @

https://www.reportconsultant.com/request_sample.php?id=4868

Stem Cell Therapy market On the basis of product,

Stem Cell Therapy market On the basis on the Applications,

In This Study, The Years Considered To Estimate the Size Of stem cell therapy Market Are As Follows:

If you have any special requirements, please let us know and we will offer you the report as you want.

Read more here:
Massive Growth for Stem Cell Therapy Market 2019 Deep Analysis of Current Trends and Future Demand by Top Key Players Osiris Therapeutics, NuVasive,...

Solve Your Problem (Skin) With These Top-Rated Acne Products From Sephora – POPSUGAR

Acne is a bummer, whether it shows up on your big day . . . or just a Monday. Chances are you've had to deal with it at some point in your life. (That's why you're reading this, right?) Whether the problem is hormonal, cystic, or something else entirely, it's pretty safe to say no one is excited when they see a new pimple in the mirror.

Now's the time to break up with breakouts for good. Here are top-rated products to add to your clear skin arsenal, straight from Sephora.

You'll find solutions to brighten and treatments to lighten (old scars), not to mention products that exfoliate skin and zap zits. There's even makeup for pimple-prone skin, too.

If you're ready to stage an acne attack (that's an attack on acne, not of acne), find the blemish-blasting products from Sephora that other shoppers are loving ahead.

Originally posted here:
Solve Your Problem (Skin) With These Top-Rated Acne Products From Sephora - POPSUGAR

The ART of Having Children – Vision Insights and New Horizons

Im looking for a sperm donor, she said.

So begins Robert Klitzmans new book. If youre imagining that Klitzman is a provocative new writer of edgy cosmopolitan fiction, guess again. In Designing Babies: How Technology Is Changing the Ways We Create Children (2020), the medical doctor explores the many ways in which babies are created today. These ARTs (assisted reproductive technologies) may seem like fiction, but theyre not. Increasing numbers of hopeful parents are investing in ART procedures.

In vitro fertilization (or IVF, the bringing together of sperm and egg outside the body) is the core ART process. Since Louise Browns birth in 1978, IVF has added more than 8 million babies to both traditional and nontraditional families. But many millions more embryos and pregnancies have been unsuccessful. The grief, frustration and financial costs can be overwhelming; even the relationship between potential parents can be ruined by the unfulfilled dream of having an ART child. Meanwhile, leftover embryos are often kept in a frozen limbo awaiting destruction, gestational adoption, or parental retrieval for another round of treatment and possible birth.

So when a friend asked Klitzman, Do you want to be the father of my child? he had plenty to think about. You wouldnt have to do anything other than donate the sperm, she assured him. He writes that although the proposition was tempting, he worried, What if I disagreed with her about how to raise our child? He eventually told her no.

I have often wondered if I made the right decision. I will never know. But the choice helped me understand the predicaments that countless potential parents confront.

We now face crucial moral, social, cultural, psychological, and existential conundrums about how to employ these technologies, he remarks; whether to monitor or control them and, if so, how; and more broadly, where as a species we are or should be heading; and what responsibilities, if any, we have in these realms.

Echoing the advice of most scientists involved in this brave new world of designing babies, he writes, We need now to enhance discussion, awareness and understandings of these issues among patients, their families, clinicians in various fields, professional organizations, policymakers, and the public at large.

Klitzman is a professor of clinical psychiatry and director of the Masters of Bioethics Program at Columbia University. He also cofounded and codirected the Center for Bioethics and is a member of the Research Ethics Advisory Panel of the US Department of Defense and of the New York State Stem Cell Commission. His previous books include, among others, The Ethics Police? (2015) and Am I My Genes? (2012).

Vision contributor Dan Cloer spoke with Klitzman about what he discovered from writing Designing Babies. The conversation began with Chinese biophysics researcher He Jiankuis reasons for proceeding with germ-line editing of human embryos.

DC He Jiankuicreated a set of guidelines called Draft Ethical Principles for Therapeutic Assisted Reproductive Technologies to support his use of CRISPR for editing human embryos last year. How would you evaluate these principles?

RK They sound good, but we need more than nice words. With ethical principles, God is in the details, so to speak. The issue with any ethical principle is how it will be interpreted and applied. And what does one do when different ethical principles conflict? In general, Hes principles are fine, but they are not complete. Most specifically, what is missing for me is that he does not address questions of risk and external review.

Its not just that there may potentially be benefits to gene editing down the line, but what are the risks for someone today? Ideally, the CRISPR gene-editing tool might be used to intervene when no alternative treatment exists and the patient will otherwise die. In this case, there are good treatments for HIV and methods for avoiding transmission of HIV to a child. Gene editing was not necessary; the risks outweighed the benefits.

Researchers and policy makers around the world struggle to lead human germ-line editing into the future.

The other crucial element in international ethical guidelines is the need for a process of external review. Its not enough for scientists to say, Im going to cure people. I made this invention in my laboratory, and Im going to give it to everyone and save their lives! There must be an outside reviewer to say, Wait a second. What is it? What are the risks? What are you going to tell people about it?

We know that every scientist has conflicts of interest. They want their discovery, intervention or innovation to work. Unfortunately, there have been many cases where scientists, in their eagerness to show that their idea works, overlook risks and problems. For instance, one of Hes principles was Organizations developing genetic cures have a deep moral obligation to serve families of every background. We know now that he had plans to develop an offshore clinic to design babies for wealthy people around the world, who would come to wherever the clinic was located. That certainly shows a conflict of interest. Was he going to provide services for poor people too? Did he feel obliged by that statement to serve everyone?

DCIVF itself is very expensivemaybe $1520,000 for one treatment cycle. Thats a high bar for many right now, even before we start adding embryo gene sequencing and, at some point, gene editing. And there is no money-back guarantee.

RKThese technologies can help us and they can hurt us. They have the potential to make us better by eliminating some diseases, but also to make us more unequal by enhancing the children of people who can pay for it.

I suspect that CRISPR will eventually be introduced at fertility clinics in various countries. Someone will come along and offer somethingIQ, physical traits, other abilitiesand it will cost thousands of dollars.

For technologies that we are using right now, like Preimplantation Genetics Diagnosis (PGD, used to examine IVF embryos for abnormalities), we already face questions of equity and access. Its great that couples who may have inherited genes associated with breast cancer can have embryos examined and screened. But the procedure is expensive and often not covered by insurance. So wealthy people can afford to screen their embryos and maybe remove a disease like breast cancer from their family. Up to now, genetic diseases have been equal-opportunity killers. In the future, I think these conditions may increasingly become diseases of the poor. Obviously a lot of social questions arise when the wealthy can remove a mutation from their gene pool while others cannot.

DCYou say that your views concerning infertility changed while writing Designing Babies. What I saw astonished me, you write. These men and women shed light on the myriad, unforeseen facets and ramifications of these new technologies and dramatically altered my views. How so?

RKI started out in some ways wary of altering the genes of future generations. But I quickly realized that there are times when it might be helpful. PGD can be used to get rid of serious diseases. The key issue is to avoid bad uses and reduce the risks. Rather than saying that designing babies will be either good or bad, the question is when is it good, and when is it bad? It is not monolithic.

DCDo you see any ethical problem in creating IVF embryos that will be tested and rejected or passed on from the clinic to the lab to be used in research? What about surrogate gestation?

RKPersonally, nobut informed consent is important. We have hundreds of thousands of unused embryos in this country. Couples understandably dont want to throw them out, but sometimes they dont want to pay for storage either. But what is the moral status of an embryo? This is also an important question in the abortion and stem-cell debates. My opinion is that if a couple is trying to avoid passing on a gene associated with a serious disease, and some embryos have that gene, then its okay not to use these embryos. These are unfortunate choices that have to be made.

Similarly, I was quite wary of the idea of buying and selling eggs or sperm, or women renting their wombs [as gestational surrogates]. There are real concerns about exploitation of women and horror stories of children abandoned when the prospective parents changed their minds and no longer wanted the child after the surrogate gave birth. But as I looked into the issue through my interviews and learned about the women who were gestational surrogates, I found that many of them were not, in fact, being exploited. They knew what they were doing: Hey, I have two or three kids of my own and if I can make $90,000 just sitting around the house, that could help me pay for my kids college education.

DCSo you began to think differently because you were no longer just at your desk mulling it over academically?

RKExactly right. I wrote this book because the public debate is still focused on whether these technologies are good or bad. Whats missing are the voices of people who are personally involved, invested. Gloria Steinem tells the story of potential exploitation and impoverished women being forced to be surrogates against their will. At least in the US, the data do not support that. Certainly exploitation is bad, and we want to avoid it. But its not clear to me that it is happening. Doing research and finding out what the lived experiences are from the people involved really opened my eyes.

This speaks to the fact that many people dont yet know much about these technologies. Its true of gene editing but also of other forms of ART: buying and selling eggs and sperm, renting wombs. It affects lots of people but goes largely unexamined because there are taboos against talking about sex and reproduction. Men dont like to talk about impotence and low sperm count, feeling it means they are not macho. Women feel great shame about the fact that their eggs arent working or that theyve had to buy someone elses eggs, and that they are therefore not genetically related to their child. Theres secrecy and fear. Parents are afraid that their daughter wont love them as much if she finds out that her mom is not actually her genetic mother. But these secrets have costs. Kids may find these things out later and can become very upset and feel betrayed. Evidence suggests that children should be told from an early age that other people helped bring them into the world, or however a parent might want to communicate that.

I also came to realize how prevalent these issues are. In Denmark, for example, 7 percent of all births occur through some form of ART, and I believe that will soon be the number in the US. This is a big issue that we need to pay more attention to, on both the personal and the policy level. The CDC [Centers for Disease Control] collect some data, but theres more to do.

DCWe dont collect and apply data very well, you say. But there are things potential users of these technologies should knowdarker things that you learned as well.

RKWe do need data, but some issues stand out even now. We know that over 40 percent of twins born through IVF have medical problems. Yet fertility doctors, using IVF, commonly implant multiple embryos to increase the odds of a successful birth; its a selling point for the clinic. If Im an IVF doctor, I can say, Look at how many live births I have. Its good marketing, but not so good for the baby. I did not know this, and many IVF patients dont know it either. Thats why many European countries that provide national health-care coverage for IVF and for neonatal intensive care units have much stricter rules than we do in the US concerning the number of embryos doctors can transfer into the womb.

A lot of data could be readily gotten, but reporting is not mandatory, and many clinics dont want to provide their statistics. Clinics that dont report are actually increasing their business, so theres almost a reverse incentive. Changes in policy could address this problem, but unfortunately the lack of data is not accidental. Many clinics dont want to tell potential customers that there may be problems; they just want to say, Well bring a baby into your life. Some clinics dont want young women they recruit as egg donors to fully understand that the procedures might cause harms, such as Ovarian Hyperstimulation Syndrome, which can have serious symptoms. Collecting and publishing more data might reveal limitations and dangers.

I would say that more information is better for those who are considering using these procedures; but some IVF doctors dont want all the data out there, and they have had sway.

DCYouve called the ART industry in the United States a kind of Wild West in terms of the relative lack of regulation. Is there a business opportunity here to form some sort of watchdog group?

RKThe American Society for Reproductive Medicine (ASRM) and other physician organizations have done a good job of coming up with guidelines in many areas, but I think they can go further. For example, ASRM permits selecting the sex of a baby for family balancing. But what does that phrase really mean? A couple has one girl and now wants a boy? Or they have four girls and now want a boy? The organization needs to be more specific. The question of enforcement also arises. In terms of egg donation, we know that young womens eggs are biologically better. But should a doctor try to get 18- to 21-year-old women to sell their eggs? How risky is this for their own reproductive future? Guidelines say doctors should not recruit such young women, but clinics often do so anyway. Hence, even when there are guidelines, many clinics dont follow them and resist stronger guidelines. Today theres little if any consequence for not adhering to them.

In this Wild West, cowboys are often doing what they want without too much supervision. There are many wonderful IVF doctors; by no means am I saying they are all bad. But oversight and greater openness to potential limitations are important.

The danger of jumping in right now and attempting to design babies using CRISPR/gene editing is that we really dont know the full effects. Patients should be able to make fully informed decisions.

DCIn the real Wild West, people knew it was wild because they had a model of what civilization looked like. But we dont have a model for reference. Were building from scratch.

RKYes. Part of this is because of ever newer technologies. But just as with implanting multiple embryos, doctors widely usedand sometimes still usetechnologies that turned out to be more harmful and less beneficial than thought. A technique called ICSI [intracytoplasmic sperm injection] took one sperm from a man with a very low sperm count and injected it directly into an egg. Now ICSI is used for two thirds of all patients, without regard to the mans fertility. But the procedure turns out to double the risk of the child having intellectual disabilities. Unfortunately many potential parents dont realize this. It may help get you pregnant, but it can cause problems.

A major challenge of the Wild West is that doctors might be making a lot of money but may not always communicate the risks as well as they should, because they have a conflict of interest: profiting from what theyre doing.

DCWhere do your books Designing Babies and Am I My Genes? overlap?

RKAt one point scientists thought they would discover the cancer gene, the alcoholic gene, the schizophrenia gene. But lo and behold, were finding out that for most common diseases and traits, many genes are involved. Diseases can also be partly genetic, partly environmental. Theres a lot of nuance.

Listing the potential causes of a disease is like describing the possible reasons for a traffic jam: Did a car break down? Was there an accident? Is a bridge closed? Is it icy? Is it rush hour? Or some combination of those?

Several companies market direct-to-consumer genetic testing, pushing the idea that these services will give you important health information and help you get control of your health. Precision medicine can indeed potentially help many people. But our genetics are complicated. Am I My Genes? explored how genetic testing serves almost as a Rorschach, with people interpreting the information in varying ways.

The idea for Designing Babies grew from my work on Genes. When I interviewed people at risk for Huntingtons, I thought I would hear about issues of discrimination or insurance. But what I heard was concerns about their kidswhether to adopt or abort, or to test embryos. I heard a very disturbing observation: If I abort or dont choose an embryo because it has the same mutation that I have, I should have been aborted; am I saying that my life was not worth living? That question still haunts me. It made me want to investigate further the ethical, moral, social and psychological questions that assisted reproductive technologies present us.

The common element and challenge that comes from both books is that we still know relatively little about genes. Its been only 60 years or so since the discovery of the DNA helix and how hereditary information is encoded. The human genome was first sequenced less than 20 years ago. Much of what we have found is not what we expected.

DNA is becoming a second language of sorts because of its most attractive promise: customized, personalized medicine.

DCYou write about individual procreative liberty. Do you have any concern that in the future parents might be pressured to use ART to avoid creating an imperfect child? Could there be a time when national health care includes or compels IVF, and that parents who opt to have children with disease will be ostracized and lose access to social services because they willingly brought a baby into the world that would require more than its share of medical and support resources?

RKPast attempts to improve the genes of people led to horrific results. Nazi Germany sought to remove bad genes by killing people. Hitler got his ideas about eugenics from the United States and our unfortunate history of racism. In the 1920s, we had eugenics fairs and better-baby contests. So we need to be very careful about efforts to improve our genes.

Given our history, however, its hard to predict what the government will do. We know that at one point the government pushed sterilization of the so-called feebleminded. And the question of abortion is obviously very contentious.

The cost of IVF will be an important factor in shaping its possible future. We dont have enough money to provide basic health services to all citizens now. So even if IVF becomes more accessible and less expensive, which I think it will to a certain degree, I dont think it will ever be mandated. People just get pregnant naturally all the time, planned or unplanned. I dont think were going to get to the point where well just not support you unless you used IVF.

DCWhat is the most important question your book helps us explore?

RKWhat kind of society do we want in terms of our ability to design babieswhether choosing or discarding certain embryos; buying and selling human eggs, sperm, and embryos; or altering genes directly?

As with all technologies, ARTs can be used for good or for bad. How do we choose the good over the bad? Do we want to live in a world where people use all of these technologies with few limits? Undoubtedly everyone in America knows someone, whether they realize it or not, who has had infertility problems and has used these technologies. These patients journeys have often been lonely and isolating.

I think the book can help open up the conversation and assist us allas individuals, as friends and family members, and as a society as a wholein figuring out how best to use these technologies for our own good.

Go here to read the rest:
The ART of Having Children - Vision Insights and New Horizons

Previous govts never thought of peoples welfare: CM – Hindustan Times

Chief minister Yogi Adityanath on Saturday said previous governments never thought about peoples welfare, while our government is continuously working on this (aspect).

He made the comment after inaugurating the new academic block of Dr Ram Manohar Lohia Institute of Medical Sciences in Lucknow.

Between 1947 and 2016, the state got 12 medical colleges. Between 2017 and 2019, 15 new medical colleges are coming up, of which seven have started admission. This is the difference in the thought process and efforts. In 70 years, 12 colleges came up. In the last three years, 15 (are being established), the chief minister said.

A proposal for 14 more medical colleges in UP had been sent to the central government, he added.

Without naming any government, the chief minister said, The central government demanded a proposal for life support ambulances but the state never sent it. When we came to power (in 2017), we got the process done in two months. At present, 250 of them (life support ambulances) have served 78,000 patients in the state. In addition, medical mobile units (MMUs) are running in 53 districts.

It is with the prime ministers vision and efforts that the state is getting two AIIMS. An effort is being made to eliminate TB by 2025 across the country, he said.

DOCTORS ASKED TO IMPROVE BEHAVIOUR

Asking doctors to improve their behaviour, Adityanath said, If you misbehave with patients, they will not come to you and your career will be finished.

Institute director Prof AK Tripathi said, We propose to start several new departments -- geriatric medicine, clinical haematology, rheumatology, hospital administration, stem cell and regenerative medicine, international medicine (climate change, tribal medicine) and plastic surgery.

Of these, geriatric medicine and clinical haematology can be started soon, Tripathi added.

The new 14-storey building inaugurated by the CM will house 240 faculty chambers, basement parking (three floors), 48 seminar rooms, four lecture theatres, each one with seats for over 200 people.

INTERNATIONAL MEDICINE DEPT LIKELY

TO ATTRACT STUDENTS

Among the new departments that have been proposed international medicine is likely to attract many students. International medicine is a field of health care, dealing with health across regional or national boundaries.

Practised very little in India, this branch will help treat international patients in a better manner, said Prof AK Tripathi.

More:
Previous govts never thought of peoples welfare: CM - Hindustan Times

Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in…

WARREN, N.J.--(BUSINESS WIRE)--Celularity, Inc. (Celularity ), a clinical-stage cell therapeutics company focused on the development of innovative allogeneic cellular therapies from human placentas, today announced pre-clinical data supporting the advancement of CYNK-001, a placental-derived, cryopreserved natural killer (NK) cell therapy, as a clinical candidate for patients with glioblastoma multiforme (GBM) in a poster presentation at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting in Phoenix, A.Z.

Results from pre-clinical studies demonstrated in vivo anti-GBM activity of CYNK-001. The positive results from these pre-clinical studies highlight the versatility and activity of our investigational, off-the-shelf, placental-derived NK cell therapy program, said Robert Hariri, M.D., Ph.D., Founder, Chairman and CEO at Celularity. There is a clear need for novel therapeutic approaches to the treatment of glioblastoma multiforme. We look forward to advancing our investigational programs and are optimistic about the possibility of bringing another therapeutic option to patients in need.

About CYNK-001CYNK-001 is the only cryopreserved allogeneic, off-the-shelf NK cell therapy being developed from placental hematopoietic stem cells as a potential treatment option for various hematologic cancers and solid tumors. NK cells are a unique class of immune cells, innately capable of targeting cancer cells and interacting with adaptive immunity. When derived from the placenta, these cells offer intrinsic safety and versatility, allowing potential use across a range of organs and tissues. CYNK-001 is currently being investigated as a treatment for acute myeloid leukemia (AML), multiple myeloma (MM), and as a potential treatment option for various solid tumors.

About CelularityCelularity, headquartered in Warren, N.J., is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta. Using proprietary technology in combination with its IMPACT platform, Celularity is the only company harnessing the purity and versatility of placental-derived cells to develop and manufacture innovative and highly scalable off-the-shelf treatments for patients with cancer, inflammatory and age-related diseases. To learn more, please visit http://www.celularity.com.

Forward-Looking StatementsThis press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Celularity expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

See the rest here:
Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in...

Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean – PRNewswire

BEVERLY HILLS, California, Nov. 21, 2019 /PRNewswire/ -- Full Alliance Group, Inc. (OTCPK: FAGI) is pleased to announce the opening of two new EBO2 treatment offices.

Dr. Yu and his staff arrived in Boca Raton, Florida, and then the Cayman Islands earlier this week with two brand-new portable EBO2 units and are currently training Dr. Joseph Purita and his staff. Dr. Purita is well-known in the stem cell and regenerative medicine sector and is eager to implement our ozone technology within his thriving practice.He has offices in Boca Raton as well as in the Cayman Islands.

Dr. Purita's Pensum Regenerative Clinic in Grand Cayman already specializes in stem cell treatment and anti-aging.The addition of EBO2 technology is expected to work synergistically with the well-established stem cell protocols already in place at the clinic.

"Expanding our footprint to the East and South, as well as the Caribbean, has been a critical part of our strategic plan," said Dr. Brian Volpp, MD, CEO and President of Full Alliance Group, Inc. "We are grateful that Dr. Purita has committed to the Yu Method and that he has made the financial commitment for two of our new units.His reputation within the stem cell community should allow ozone therapy to become more mainstream as he gains more experience with integrating EBO2 into his existing protocols."

Also, we have been advised by our legal team that the third quarter financial filing must be made publicly available to all shareholders. Consequently, the filing has been posted on our website:https://FullAlliance.com

About Full Alliance Group Inc.

Full Alliance Group Inc. (OTCPK: FAGI) is a multi-faceted holding company with various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc., a wholly owned subsidiary of Full Alliance Group, develops, markets, and distributes a proprietary line of nutraceutical products. EBO2, Inc., a wholly owned subsidiary of Full Alliance Group, is the provider of ''EBO2'', a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone. The unit allows extracorporeal blood and oxygenation, ozone exposure and blood filtration.The process filters blood in a unique way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins which are in excess in the venous blood supply. The EBO2 unit is considered the world's most advanced medical ozone therapy.

For additional information regarding Full Alliance Group, visit, http://www.fullalliance.com.

Paul Brian Volpp, MD, MPH, President / CEO The Full Alliance Group

Forward-Looking StatementsThis shareholder update may contain a number of forward-looking statements. Words and variations of words such as: "expect", "goals", "could", "plans", "believe", "continue", "may", "will", and similar expressions are intended to identify our forward-looking statements, including but not limited to: our expectation for growth, benefits from brand-building, cost savings and margins. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond our control, which could cause our actual results to differ materially from those indicated in our forward-looking statements. Such factors include, but are not limited to: continued volatility of, and sharp increase in: costs/pricing actions, increased competition, ability to raise sufficient operating capital, risks from operating internationally, consumer weakness, weakness in economic conditions and tax law changes.

Full Alliance Group Inc. Investor RelationsDave DonlinEmail: Info@TheCervelleGroup.comPhone: (407) 490-6635Web: http://www.StockInvestorDaily.comVisit: http://www.fullalliance.comContact: ir@fullalliance.com

SOURCE Full Alliance Group, Inc.

Home

Continue reading here:
Full Alliance Group Announces New EBO2 Sites in Florida and the Caribbean - PRNewswire

Allogene and the need for a reliable cell source – Vantage

David Chang saw the end goal early. As chief medical officer of Kite Pharma, before that company was ever in allogeneic cell therapy, he did a deal with UCLA to secure a supply of pluripotent stem cells. Now, as chief executive of Allogene, he has repeated the trick, licensing in Notch Therapeutics stem cell technology this month.

Speaking to Vantage at this weeks Jefferies conference in London Mr Chang said that within a month of Allogenes creation he recognised the need to secure cell supply and of course he had done it before, at Kite. Any allogeneic cell therapy company at some point has to start thinking about renewable cell source, he states.

Since the 2017 approvals of Kymriah and Yescarta the development of autologous cell therapy products has stalled, and many investors see allogeneic, or off-the-shelf, therapy as the breakthrough that will move the needle.

However, the first generation of allogeneic players have hit production bottlenecks, and have struggled with cells derived from healthy donors; these tend to be heterogeneous and of variable quality not what is needed when the goal is to produce a reliable, universal product.

Single cell

Using induced pluripotent stem cells (iPSCs) as the source, however, is likened by another player in this field, Fate Therapeutics, to going by monoclonal antibody principles: starting from a single cell line.

The idea is that virtually any adult cell can, in a petri dish, be regressed to an iPSC phenotype, and this, using clever science, can then be reprogrammed into a defined mature cell that can be infinitely expanded.

What the iPSC is differentiated into depends on each developers focus: Allogene is clearly working on T cells, whereas Fate is initially targeting NK cell therapeutics. Each comes with its own degree of difficulty, and Mr Chang argues that differentiating iPSCs into NK cells is possibly easy.

He says Allogene actively went out to source such a technology, and there were several potential partners, though of course the UCLA work was no longer available. Without going into scientific minutiae, the Notch teams underlying concept is the same as that of UCLA, says Mr Chang.

However, the Notch approach is a serum-free, cell-free system to differentiate iPSCs. The UCLA technology, pioneered by Dr Gay Crooks andalso known as an artificial thymic organoid, uses so-called feeder cells on top of which the desired iPSC-derived cells are differentiated.

All that said, the Notch deal caused a degree of consternation, with some Allogene investors seeing it as demonstrating a lack of confidencein Cellectiss donor-derived approach.

Mr Chang says he was taken aback by such pushback, and stresses that the transition from autologous to allogeneic is not a bet on a single technology but a stepwise process. Nevertheless, the clear implication is that, in time, Cellectis's current healthy donor cell source approach will become obsolete.

Though Mr Chang accepts that the science is not quite there to implement the Notch technology into clinical programmes, he says: The way we see the future, whether its five or 10 years down the line, is in the renewable cell source.

Go here to see the original:
Allogene and the need for a reliable cell source - Vantage

Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis – Downey Magazine

In autologous stem cell and non-stem cell based therapies, an individuals cell is cultured and then re-introduced to the donors body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkins lymphoma, Parkinsons disease, Hodgkins lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years.

The report is a thorough analysis of theAutologous Stem Cell and Non-Stem Cell Based Therapies Market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.

Request a PDF Brochure of Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market.

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future.

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss, nausea, severe infections, vomiting, heart complications, and infertility.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America.

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market.

Request for a Discount on Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=4001

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.

The rest is here:
Autologous Stem Cell and Non Stem Cell Based Therapies Market Shares, Strategies, and Forecasts Analysis - Downey Magazine

Human Embryonic Stem Cells (HESC) Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 – Chronicles 360

The Global Human Embryonic Stem Cells (HESC) Market Outlook Report is a comprehensive study of the Human Embryonic Stem Cells (HESC) industry and its future prospects.. A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Human Embryonic Stem Cells (HESC) Market.

Read Report Details at https://www.proaxivereports.com/51901

List of key players profiled in the report:

ESI BIOThermo FisherBioTimeMilliporeSigmaBD BiosciencesAstellas Institute of Regenerative MedicineAsterias BiotherapeuticsCell Cure NeurosciencesPerkinElmerTakara BioCellular Dynamics InternationalReliance Life SciencesResearch & Diagnostics SystemsSABiosciencesSTEMCELL TechnologiesStemina Biomarker DiscoveryTakara BioTATAA BiocenterUK Stem Cell BankViaCyteVitrolife

Request for Sample Report athttps://www.proaxivereports.com/request-sample/51901

TheHuman Embryonic Stem Cells (HESC)Market Segmentation:

Product Product Type Segmentation SegmentationTotipotent Stem CellsPluripotent Stem CellsUnipotent Stem Cells

Industry SegmentationResearchClinical Trials

The report analyses the Human Embryonic Stem Cells (HESC) Market By Type and By Country for the historical period of 2017-2018 and the forecast period of 2019-2024.

Region Segmentation of Human Embryonic Stem Cells (HESC) Market

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Ask more details or request custom reports to our experts athttps://www.proaxivereports.com/pre-order/51901

The report has covered and analyzed the potential of Human Embryonic Stem Cells (HESC) market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the Human Embryonic Stem Cells (HESC) market report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities. Additionally, the report also highlights market entry strategies for various companies.

Scope of the Human Embryonic Stem Cells (HESC) Market Report

Human Embryonic Stem Cells (HESC) Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)Human Embryonic Stem Cells (HESC) Market Size, Growth, ForecastAnalysis By Type:

Regional Analysis Actual Period: 2017-2018, Forecast Period: 2019-2024Human Embryonic Stem Cells (HESC) Market Size, Growth, ForecastHuman Embryonic Stem Cells (HESC) Market Analysis By Type

Report HighlightsCompetitive Landscape: Company Share AnalysisMarket Dynamics Drivers and Restraints.Market TrendsPorter Five Forces Analysis.SWOT Analysis.Company Analysis

Purchase Human Embryonic Stem Cells (HESC) Market Report athttps://www.proaxivereports.com/checkout/51901

View post:
Human Embryonic Stem Cells (HESC) Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2024 - Chronicles 360

Tokyo’s Heartseed reaps $26M to test its stem cell injections for heart failure – FierceBiotech

Tokyo-based Heartseed has raised 2.8 billion yen, or about $26 million U.S., to help develop its stem cell-based treatment for heart failure.

The company has its eyes on two clinical trials, set to start in the next year: an investigator-initiated study through its research partner Keio University in dilated cardiomyopathy, followed by a phase 1/2 trial in late 2020 for heart failure with reduced left ventricular ejection fraction.

Heartseeds treatment differs in approach from other, similar therapies using induced pluripotent stem cells (iPSCs), where sheets of cells are grafted onto the surface of the heart to improve vascularization and blood flow.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Instead, the company forms spherical clusters of heart cells from purified, allogeneic iPSCs, which are injected directly into the heart muscle wall. As they grow and electrically sync with other cells within the myocardium, Heartseed expects to see improvements in the strength of contractions.

The companys series B round included new investors SBI Investment, JMDC, Gene Techno Science, Nissay Capital and SMBC Capital as well as Astellas Venture Management, returning from Heartseeds series A raise. The latest proceeds bring its total funding to 3.8 billion yen, or about $35 million.

RELATED: Growing transplantable arteries from stem cells

Heartseed was founded in 2015 through the research of its CEO, Keiichi Fukuda, a professor in the department of cardiology at Keio University, and his teams work in regenerative medicine and cell production, purification and delivery.

We are grateful for the support of our investors, which I believe is a reflection of their expectation and confidence that our lead pipeline HS-001 can be a curative therapy for severe HF, with the mechanism that transplanted ventricular-specific highly-purified cardiomyocytes engraft to patients heart and retain for a long-term, Fukuda said in a statement.

Read this article:
Tokyo's Heartseed reaps $26M to test its stem cell injections for heart failure - FierceBiotech